Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 688 across all filing types
Latest filing 2021-03-04 Earnings Release
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Résultats annuels 2020 : Avancées majeures dans la NASH et visibilité financière significativement étendue suite au succès de l’introduction en bourse aux États Unis
Earnings Release Classification · 95% confidence The document is an 'Earnings Release' (ER) for the fiscal year 2020. It contains key financial highlights, such as cash position, revenue, R&D expenses, and net results, along with management commentary on clinical trial progress and business outlook. It is not a full Annual Report (10-K) as it lacks the comprehensive audited financial statements and extensive disclosures required for such filings, and it is not a mere announcement of a report (RPA) because it provides substantive financial data and analysis. FY 2020
2021-03-04 French
2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States
Earnings Release Classification · 98% confidence The document is titled "2020 Full-Year Results" and contains detailed financial figures for the year ended December 31, 2020, compared to 2019. It includes an income statement table, discussions on revenues, R&D expenses, cash flow from operating/investing/financing activities, and a net loss figure. This structure is characteristic of a comprehensive annual financial report. Although it is presented as a press release dated March 4, 2021, the content is the full-year financial performance review. In the context of SEC filings, the comprehensive annual report is the 10-K. Since this document provides the full-year financial details and performance review, it aligns best with the 'Annual Report' category (10-K), even if it's the press release version accompanying the official filing. FY 2020
2021-03-04 English
Inventiva annonce une collaboration pour développer des biomarqueurs non-invasifs permettant l’identification de patients chez lesquels lanifibranor conduit à une résolution de la NASH et à une amélio
Regulatory Filings Classification · 95% confidence The document is titled with a headline announcing a collaboration and contains detailed information about a scientific partnership, clinical trial data (Phase IIb NATIVE, planned Phase III NATIV3), quotes from management and the collaborating scientist, and concludes with standard 'About the Company' and 'Forward-Looking Statements' sections, all under the heading 'COMMUNIQUE DE PRESSE' (Press Release). This structure strongly indicates an official announcement of news or development, rather than a formal regulatory filing like a 10-K, an earnings release (ER) which focuses only on key results, or a full report (IR/AR). Since it is a press release announcing a strategic development (collaboration on biomarkers), it fits best under the general category for regulatory announcements that aren't otherwise specified, which is Regulatory Filings (RNS), although it could also be argued as a general corporate update. Given the context of financial reporting databases, press releases announcing strategic partnerships or scientific milestones are often categorized as RNS if they don't fit a more specific financial/governance code. However, since it is a detailed announcement of a business/scientific development, and not just a brief notice of report publication (RPA), RNS is the most appropriate fallback for a press release of this nature.
2021-02-25 French
Inventiva announces collaboration on non-invasive biomarkers to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvemen
Earnings Release Classification · 99% confidence The document is a press release dated February 25, 2021, announcing a collaboration between Inventiva and Professor Jérôme Boursier regarding the development of non-invasive biomarkers for NASH treatment response to lanifibranor. It details scientific objectives, mentions upcoming clinical trials (NATIV3 Phase III), and includes standard sections like 'About Inventiva' and contact information. This format—a formal announcement of a significant business/scientific development, often released via wire services—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change announcement (MANG), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general announcement. Given the content focuses on a strategic partnership and clinical development update, it is a form of corporate news release. In the context of the provided definitions, this type of announcement, which is not a formal financial statement or a specific regulatory filing like DIRS or DIV, often falls under the 'Earnings Release' category if it's a periodic update, or 'Regulatory Filings' (RNS) if it's purely informational. However, press releases detailing clinical progress and strategic partnerships are frequently categorized as ERs, even if they don't contain quarterly numbers, as they are key investor communications. Since it is a formal announcement of news rather than a report itself, and it's not a proxy or dividend notice, ER is the most appropriate fit for a significant corporate update press release. FY 2021
2021-02-25 English
Inventiva participera à plusieurs conférences investisseurs en mars 2021
Regulatory Filings Classification · 99% confidence The document is a press release dated February 24, 2021, announcing that the company's CEO will participate in several investor conferences in March 2021. The content details the names, dates, and formats of these upcoming investor events (e.g., 'Credit Suisse Virtual 2021 London Global Healthcare Conference', 'H.C. Wainwright Virtual Global Life Sciences Conference', '33rd Virtual Annual Roth Conference'). This type of announcement, which schedules management participation in investor-facing events, is best classified as an Investor Presentation (IP) or related communication, as it is designed to present company information to investors. Since the document itself is an announcement about future presentations rather than the presentation slides or a transcript of a call, and it focuses on scheduling management appearances at investor conferences, 'Investor Presentation' (IP) is the most fitting category, as it relates directly to investor outreach activities. It is not a formal regulatory filing like 10-K, ER, or IR, nor is it a transcript (CT) or a general regulatory notice (RNS).
2021-02-24 French
Inventiva to participate at several investor conferences in March 2021
Report Publication Announcement Classification · 99% confidence The document is a press release dated February 24, 2021, announcing that the company, Inventiva, will participate in several upcoming investor conferences in March 2021. It details the names, dates, and formats of these events (Credit Suisse Virtual 2021 London Global Healthcare Conference, H.C. Wainwright Virtual Global Life Sciences Conference, and 33rd Virtual Annual Roth Conference). This type of announcement, which informs investors about participation in external industry events, does not fit the definitions for formal financial reports (10-K, IR, ER, MRQ), regulatory filings (RNS), or specific corporate actions (DIV, CAP, SHA). It is best classified as an Investor Presentation/Update related activity, but since the core content is about *attending* conferences rather than *releasing* a presentation document itself, it falls under general investor relations communication. Given the options, this announcement is most closely related to investor engagement activities. Since there is no specific code for 'Investor Conference Participation Announcement', and it is not a formal report or a management change, it is a general communication to investors. However, the closest category that deals with investor-facing materials, even if it's an announcement *about* participation, is often grouped near Investor Presentations (IP) or sometimes treated as a general Regulatory Filing (RNS) if it's a required disclosure. Given the context of financial reporting databases, announcements about participation in major investor conferences are often categorized under Investor Presentation (IP) or a similar investor relations category. Since the document is an announcement about future investor meetings/presentations, IP is the most contextually relevant choice among the specific options, although RPA (Report Publication Announcement) is also a possibility if this were seen as announcing an upcoming presentation. Given the focus on future investor engagement, IP is selected as the primary intent.
2021-02-24 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.